Group 1 - The eighth China International Import Expo opened on November 5, showcasing Gilead's commitment to creating a healthier world with a 500 square meter exhibition space [1] - Gilead presented two Asia debut products: long-acting HIV pre-exposure prophylaxis drug Lenacapavir and a new drug for primary biliary cholangitis (PBC) Seladelpar, along with 13 innovative drugs launched in China [1] - Gilead's global vice president and general manager for China, Jin Fangqian, emphasized the company's accelerated development in China, highlighting the transformation of several "Expo babies" from exhibits to commercial products [1] Group 2 - Gilead plans to sign nearly ten cooperation projects at the expo to enhance the accessibility of innovative drugs and promote standardized diagnosis and treatment [2] - Jin Fangqian expressed confidence in Gilead's long-term development in China, citing the country's efforts in expanding openness, strengthening intellectual property protection, and optimizing the business environment [2] - The company aims to support the high-quality development of China's healthcare sector and contribute to the "Healthy China 2030" goal [2]
吉利德科学携亚洲首发展品亮相第八届进博会